137 related articles for article (PubMed ID: 21574264)
1. Determination of robustness and optimal work conditions for a purification process of a therapeutic recombinant protein using response surface methodology.
Amadeo I; Mauro LV; Ortí E; Forno G
Biotechnol Prog; 2011; 27(3):724-32. PubMed ID: 21574264
[TBL] [Abstract][Full Text] [Related]
2. Industry perspective on the validation of column-based separation processes for the purification of proteins. Parenteral Drug Association.
J Parenter Sci Technol; 1992; 46(3):87-97. PubMed ID: 1522447
[TBL] [Abstract][Full Text] [Related]
3. Multiproduct Resin Reuse for Clinical and Commercial Manufacturing-Methodology and Acceptance Criteria.
Sharnez R; Doares S; Manning S; Mehta K; Mahajan E; To A; Daniels W; Glynn J; Dhamane S; Wen X; Wang Y; Gour P; Guenther C; Foley D; Hayes R; Mott A; Prabhu S; Tavalsky D; Hendershot M; Haas D; Hesslein A; Schuelke N; Tjandra H
PDA J Pharm Sci Technol; 2018; 72(6):584-598. PubMed ID: 30030349
[TBL] [Abstract][Full Text] [Related]
4. Predicting the performance of chromatographic columns in protein purification processes.
Mao QM; Prince IG; Hearn MT
Australas Biotechnol; 1992 Apr; 2(2):112-6. PubMed ID: 1368922
[TBL] [Abstract][Full Text] [Related]
5. Design space approach in the optimization of the spray-drying process.
Lebrun P; Krier F; Mantanus J; Grohganz H; Yang M; Rozet E; Boulanger B; Evrard B; Rantanen J; Hubert P
Eur J Pharm Biopharm; 2012 Jan; 80(1):226-34. PubMed ID: 21983606
[TBL] [Abstract][Full Text] [Related]
6. Establishment of a design space for biopharmaceutical purification processes using DoE.
Amadeo I; Mauro L; Ortí E; Forno G
Methods Mol Biol; 2014; 1129():11-27. PubMed ID: 24648063
[TBL] [Abstract][Full Text] [Related]
7. Application of hydrophobic interaction displacement chromatography for an industrial protein purification.
Sunasara KM; Xia F; Gronke RS; Cramer SM
Biotechnol Bioeng; 2003 May; 82(3):330-9. PubMed ID: 12599260
[TBL] [Abstract][Full Text] [Related]
8. Using partition designs to enhance purification process understanding.
Pieracci J; Perry L; Conley L
Biotechnol Bioeng; 2010 Dec; 107(5):814-24. PubMed ID: 20632374
[TBL] [Abstract][Full Text] [Related]
9. Application of quality by design principles to the development and technology transfer of a major process improvement for the manufacture of a recombinant protein.
Looby M; Ibarra N; Pierce JJ; Buckley K; O'Donovan E; Heenan M; Moran E; Farid SS; Baganz F
Biotechnol Prog; 2011; 27(6):1718-29. PubMed ID: 21948302
[TBL] [Abstract][Full Text] [Related]
10. Protein purification using chromatography: selection of type, modelling and optimization of operating conditions.
Asenjo JA; Andrews BA
J Mol Recognit; 2009; 22(2):65-76. PubMed ID: 18546092
[TBL] [Abstract][Full Text] [Related]
11. Current issues in validation of chromatography.
Sofer G
Dev Biol (Basel); 2003; 113():61-4. PubMed ID: 14620853
[TBL] [Abstract][Full Text] [Related]
12. Liquid chromatography of recombinant proteins and protein drugs.
Geng X; Wang L
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Apr; 866(1-2):133-53. PubMed ID: 18294930
[TBL] [Abstract][Full Text] [Related]
13. Recombinant protein purification using gradient assisted simulated moving bed hydrophobic interaction chromatography. Part II: process design and experimental validation.
Gueorguieva L; Palani S; Rinas U; Jayaraman G; Seidel-Morgenstern A
J Chromatogr A; 2011 Sep; 1218(37):6402-11. PubMed ID: 21824621
[TBL] [Abstract][Full Text] [Related]
14. Effect of system variables involved in packed column supercritical fluid chromatography of stavudine taken as model analyte using response surface methodology along with study of thermodynamic parameters.
Kaul N; Agrawal H; Paradkar AR; Mahadik KR
J Pharm Biomed Anal; 2007 Jan; 43(2):471-80. PubMed ID: 16935453
[TBL] [Abstract][Full Text] [Related]
15. High-throughput process development for recombinant protein purification.
Rege K; Pepsin M; Falcon B; Steele L; Heng M
Biotechnol Bioeng; 2006 Mar; 93(4):618-30. PubMed ID: 16369981
[TBL] [Abstract][Full Text] [Related]
16. Demonstrating β-glucan and yeast peptide clearance in biopharmaceutical downstream processes.
Jiang C; Scherfner S; Dick LW; Mahon D; Qiu D; Cheng KC; Shukla AA
Biotechnol Prog; 2011; 27(2):442-50. PubMed ID: 21365784
[TBL] [Abstract][Full Text] [Related]
17. Rapid whole monoclonal antibody analysis by mass spectrometry: An ultra scale-down study of the effect of harvesting by centrifugation on the post-translational modification profile.
Reid CQ; Tait A; Baldascini H; Mohindra A; Racher A; Bilsborough S; Smales CM; Hoare M
Biotechnol Bioeng; 2010 Sep; 107(1):85-95. PubMed ID: 20506289
[TBL] [Abstract][Full Text] [Related]
18. Process characterization of the chromatographic steps in the purification process of a recombinant Escherichia coli-expressed protein.
Rathore AS; Johnson GV; Buckley JJ; Boyle DM; Gustafson ME
Biotechnol Appl Biochem; 2003 Feb; 37(Pt 1):51-61. PubMed ID: 12578552
[TBL] [Abstract][Full Text] [Related]
19. Demonstration of robust host cell protein clearance in biopharmaceutical downstream processes.
Shukla AA; Jiang C; Ma J; Rubacha M; Flansburg L; Lee SS
Biotechnol Prog; 2008; 24(3):615-22. PubMed ID: 18410156
[TBL] [Abstract][Full Text] [Related]
20. Chromatographic purification of recombinant human erythropoietin.
Adamíková J; Antošová M; Polakovič M
Biotechnol Lett; 2019 May; 41(4-5):483-493. PubMed ID: 30810853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
